Previous Article | Next Article ![]()
Journal of Virology, October 2001, p. 9966-9976, Vol. 75, No. 20
Department of Microbiology and
Immunology1 and Department of
Comparative Medicine,2 Stanford University
School of Medicine, Stanford, California 94305-5124
Received 26 March 2001/Accepted 3 June 2001
The murine cytomegalovirus CC chemokine homolog MCK-2 (m131-129) is
an important determinant of dissemination during primary infection.
Reduced peak levels of viremia at day 5 were followed by reduced levels
of virus in salivary glands starting at day 7 when mck
insertion (RM461) and point (RM4511) mutants were compared to
mck-expressing viruses. A dramatic MCK-2-enhanced
inflammation occurred at the inoculation site over the first few days
of infection, preceding viremia. The data further reinforce the role of
MCK-2 as a proinflammatory signal that recruits leukocytes to increase the efficiency of viral dissemination in the host.
Primary infection with human
cytomegalovirus (CMV) is associated with shedding in saliva and other
body fluids (42). This virus encodes functions that
modulate the host immune response (22, 23) and that
influence host cell or tissue tropism (39). Due to the
strict species specificity of CMVs, murine CMV has been used to gain
insights into viral pathogenesis and latency (24), host
immune control of virus infection (27), and viral modulation of the host immune response (22, 23). Human and murine CMVs have a colinear genome organization (46) and
encode immunomodulatory functions that carry out analogous functions during infection (22, 23). Gene products that function in similar ways sometimes retain little amino acid sequence similarity in
these two viruses. For example, murine and human CMVs rely on
nonhomologous gene products to downmodulate major histocompatibility complex class I gene expression (1, 22, 23, 25, 61), and
both have major histocompatibility complex class I homologs that are
nonhomologous themselves, although both influence natural killer cell
behavior (17, 31, 47).
The chemokine receptor US28 (20, 41, 56) is not conserved
in murine CMV, although two other seven-transmembrane-spanning G-protein-coupled receptor homologs, M33 and M78, are
(46). Both murine and human CMVs encode gene products with
chemokine-like activities (35, 36, 43, 49); however, they
represent different chemokine classes and lack amino acid sequence
similarity. The human CMV UL146 gene encodes vCXC-1, a CXC chemokine
(43), and the murine CMV m131-129 gene encodes MCK-2, a CC
chemokine homolog (19, 35, 36, 49). Viral chemokine
homologs (3, 14, 30, 33, 40, 67) may function as
chemokines to increase leukocyte migration or may act as antagonists
that block the migration of leukocyte subsets (6, 13, 15, 16, 26,
28, 43, 49, 54) to host chemokines (4, 7, 48, 63).
Chemokines regulate cell effector functions such as granule release and
cytokine expression, contributing to both the quality and the magnitude of inflammatory responses (2, 11, 34, 50, 58, 66). Human
CMV vCXC-1 activates neutrophils via CXCR2 very much like interleukin 8 (43) and could influence neutrophil behavior (21, 51). Murine CMV open reading frame (ORF) m131 was initially predicted to encode an 81-aminio-acid (aa) chemokine,
designated MCK-1, based on the presence of C spacing motifs typically
conserved in CC chemokines (36). A predicted processed
63-aa synthetic form of MCK-1 was found to induce calcium flux on
murine peritoneal macrophages and THP-1 cells but to
neither bind to nor inhibit the binding of host chemokines to other
leukocyte populations (49). This behavior led us to
propose a model where MCK-1 recruits a subset of mononuclear leukocytes
during viral infection (49; N. Saederup, Y. C. Lin, T. Schall, and E. S. Mocarski, Abstr. 23rd International
Herpesvirus Workshop, York, England, abstr. 340, 1998).
The principal transcript arising from the m131 region was found to
contain an intron such that the spliced mRNA created an in-frame fusion
between MCK-1 and 199 codons that included the entire m129 ORF
(19, 35). This m131-129 fusion was denoted MCK-2
(35) and was shown to be expressed as a true late
( Murine CMV disseminates in two distinct phases (12) via
peripheral blood mononuclear leukocytes (5, 55). Primary
viremia within 2 days after inoculation (12) is believed
to seed sites such as the spleen, liver, lungs, and brown fat
(12, 55). A readily detected secondary viremia peaks at 5 days after inoculation (12, 49, 55); from this the
salivary glands, a major site of murine CMV replication and
shedding, become seeded (55). Five recombinant
viruses, RM461 (8, 55) (Fig.
1), RM
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.20.9966-9976.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Murine Cytomegalovirus CC Chemokine Homolog MCK-2 (m131-129) Is a
Determinant of Dissemination That Increases Inflammation at Initial
Sites of Infection
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References
2) gene product (60) secreted
into the medium during infection (35). Although
functional evaluation of MCK-2 has not been undertaken, studies of
synthetic MCK-1 (49) predicted that MCK-2 would be proinflammatory because all 81 aa of MCK-1 are contained in MCK-2. Consistent with this prediction, mck mutant viruses
exhibited reduced levels of viremia and poor dissemination to salivary
glands (19, 49, 55) without having an impact on
dissemination to other organs, such as the spleen, liver, and lungs.
Reduced dissemination to salivary glands appeared independent of the
capacity to mount an adaptive immune response (55) but may
be influenced by the natural killer cell response (19).
461-1 (8),
m131Z
(19),
m131ns (19), and RM4485
(49), all of which carry mutations in the mck
gene, have been shown to exhibit reduced peak titers in salivary
glands. RM461 and RM4485 were shown to exhibit reduced peak levels of
viremia (49). It has been found that dissemination of
mck mutant viruses to other organs, including the spleen,
liver, lungs, adrenal glands, kidneys, and brown fat, remains largely
unaltered (8, 49, 55). Latency and reactivation
characteristics of mck mutants are similar to those of
wild-type viruses (8). We undertook the current study to
investigate the nature of the impact of mck expression on
the behavior of virus or host cells at the site of inoculation. Our study shows that mck expression is associated with a strong
cellular inflammatory response at the site of inoculation and that this activity is dependent on the conserved CC chemokine motif in
mck gene products.

View larger version (27K):
[in a new window]
FIG. 1.
Schematic representation of mutant virus genomes. The
top line represents a restriction map of the HindIII K,
L, and J DNA fragments in murine CMV strain K181+,
corresponding to nts 173170 to 195847 of the Smith strain genome
(46) (GenBank accession number U68299). Restriction
sites for HindIII and selected BssHI,
HpaI, and BbrPI sites are indicated above
the line, and a 1-kbp scale marker is indicated by a double-headed
arrow below the line. Open boxes with arrowheads depict the positions
of viral ORFs, with m131 and m129 contributing the coding sequences for
MCK-2 (35). m130 overlaps mck on the
opposite DNA strand (46). Solid arrows depict transcripts
(ie1, ie3, ie2,
mck, and sgg1) encoded by wild-type
viruses. The mutations introduced into mutant viruses
RM427+, RM4503, RM461, and RM4511 are depicted below the
transcripts. The 3.9-kbp lacZ insert carried by
RM427+ and RM461 (open box) is controlled by a 199-bp human
CMV ie1-ie2 promoter fragment (shaded
box) encompassing positions
219 to
19 relative to the transcription
start site (8, 37, 55). The 1.7-kbp EGFP-puro insert in
RM4503 and RM4511 (open box) is controlled by a 248-bp human CMV
ie1-ie2 promoter fragment (hatched box)
encompassing positions
242 to +7 relative to the transcription start
site (59). The expanded region shows aa 25 to 30 of m131
and aa 142 to 147 of m130, including the two nucleotide point mutations
(denoted by asterisks) introduced into RM4511, generating a new
BbrPI site (underlined) and altering the MCK-2 amino
acid sequence (C27R and C28G; bold type).
Wild-type strain K181+ nucleotide and amino acid sequences
are shown at the bottom.
Construction of recombinant viruses to assess the mck chemokine motif. First, we isolated RQ461, a rescue of the mck mutation in RM461 (49, 55). Then, we constructed mutant virus RM4511, with a mutation in the conserved CC chemokine motif (Fig. 1). Rescued virus RQ461 was constructed by transfecting MluI-linearized pON4457 into RM461-infected cells by use of Superfect (Qiagen, Valencia, Calif.) and, after harvesting at 72 hours postinfection, expanding viral progeny at a low multiplicity of infection (<0.1) on NIH 3T3 cells. pON4457 (59) carries a wild-type murine CMV DraI/EcoRI fragment (nucleotides [nts] 183086 to 189674), spanning the sgg1, mck, and ie2 genes, as well as the major immediate-early enhancer, cloned into pGEM-2 (Promega, Milwaukee, Wis.).
To select for recombinants and to reduce the likelihood of isolating viruses with adventitious mutations (55), the virus pool was passaged twice through mice by inoculating footpads and screening salivary gland sonicates 14 days later for lacZ-deficient plaques. Viruses were isolated and subjected to three rounds of limiting dilution purification. White plaques were observed with pON4457 but not with control plasmid pME18S (57). Initially, two independent isolates of RQ461 were selected based on replacement of the lacZ insert with a wild-type copy of the mck gene (Fig. 1). Both of these isolates exhibited growth properties similar to those of the wild-type parental virus, and one of these was designated RQ461. The RQ461 genome structure was compared to those of RM461 and K181+ by separation of [
-32P]dCTP-end-labeled
HindIII-digested virion DNA by agarose gel electrophoresis. Virion DNA (0.5 to 1.0 µg) was digested with HindIII, BssHII, AflII, or
SpeI (New England Biolabs, Beverly, Mass.) and end labeled
in the presence of 2.5 µCi of [
-32P]dCTP
(Amersham), 125 µM each dATP, dGTP, and dTTP, and 0.5 U of
Klenow polymerase (Roche, Indianapolis, Ind.) for 15 min at room
temperature in 20 µl of restriction enzyme buffer. Restriction fragments were separated on a 0.6% agarose gel, which was fixed in
95% ethanol and vacuum dried at 80°C, followed by autoradiography. RQ461 displayed a restriction pattern distinct from that of mutant RM461 but similar to that of wild-type K181+
(Fig. 2). Restriction digest analysis
using AflII, HpaI, or SspI showed that
the genome of the rescued virus did not contain detectable adventitious deletions or rearrangements (data not shown).
|
-galactosidase substrate 5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside
(X-Gal) overlay (37) to confirm the absence of parental
virus RM427+ (<1
plaque/106 PFU).
RM4511 DNA was subjected to blot hybridization analysis to detect the
introduced BbrPI site by following established protocols (37, 44, 60). A HindIII/AflII
fragment from pON4457 (murine CMV nts 187890 to 188578) was
radiolabeled with [
-32P]dCTP as an
mck probe (18). This detected 1,097 and 591-bp BbrPI restriction fragments in RM4511
DNA. DNA from parental virus RM427+ or
EGFP control virus RM4503 (59) had only the expected
1,688-bp BbrPI fragment (Fig.
3A) of the wild-type mck gene.
Thus, the substitution mutations had been introduced at the correct
genomic locations. To confirm the position of the EGFP-puro
insert, end-labeled BssHII DNA fragments were generated from
all viruses, separated by agarose gel electrophoresis, and subjected to
autoradiography to reveal a 7.9-kbp RM4511 fragment in place of
the 8.3-kbp fragment observed in parental virus
RM427+ (Fig. 3B). Thus, the EGFP-puro cassette
was inserted within the ie2 gene of RM4511 in a manner
similar to that in RM4503 (59). RM4511 DNA was also
digested with HindIII, generating the expected 8.5-kbp
fragment instead of the two fragments (3.7 and 7.3 kbp) found in
RM427+ DNA. No adventitious genomic
deletions or rearrangements were detected in RM4503 or either of the
RM4511 isolates when subjected to HindIII,
SpeI, or BssHII restriction analysis (Fig. 3C and data not shown). Together, these results demonstrated that both independent RM4511 isolates carried the intended substitution mutations
in mck and the marker gene insert in ie2. As
expected from extensive analyses of previous ie2
mck double mutants in cultures and in mice (8),
the two independent RM4511 isolates produced peak titers in NIH 3T3
cells that were indistinguishable from those of
K181+ and RM427+ (data not
shown).
|
Role of mck in peripheral blood mononuclear cell-associated viremia. Previous studies of mck mutant viruses in mice suggested that this gene affected the behavior of host mononuclear cells in a way that resulted in poor dissemination to salivary glands (8, 19, 49, 55). Although our studies have discounted any impact on the adaptive immune response or viral latency, one study suggested that mck modulated the host immune response (19). To date, precise m131-specific mutations have not been studied, so differences in the behavior of mutant viruses may have resulted from an impact on viral genes, such as m130, that overlap m131 (19, 49). We compared the growth properties of mck mutants and control viruses, initially evaluating peak levels of viremia at 5 days postinoculation (106 PFU, intraperitoneal [i.p.] route). PBLs were collected from CO2-asphyxiated mice for coculturing with permissive NIH 3T3 cells. Peripheral blood leukocytes (PBLs) were washed, suspended in growth medium at 106 cells/ml, serially diluted, and subjected to an infectious-center assay on NIH 3T3 cells overlaid with complete growth medium (37) containing 0.75% carboxymethyl cellulose. For this and all other experiments, groups of female mice (3 to 5 weeks of age) were used with the approval of the Stanford Administrative Panel on Laboratory Animal Care.
Peak viremia was reduced 50- to 100-fold in mice infected with RM461 compared to either rescued virus RQ461 or parental wild-type virus K181+ (Fig. 4A), consistent with previous observations (49). To investigate the contribution of the conserved chemokine sequence motif in m131, mice were inoculated with RM461, RM4511.1, RM4511.2, RM4503, or RM427+; PBLs were harvested at 5 days postinoculation for assay. The previously observed decrease in RM4511.1 or RM4511.2 infection resulted in peak viremia that was 25- to 50-fold lower than that seen with either parental virus RM427+ (Fig. 4B) or control virus RM4503 (Fig. 4C). These results showed that mck expression correlated with increased viremia, that mck function depended upon the conserved CC motif, and that the m130 ORF did not contribute to the phenotype.
|
Dissemination of mck mutants after inoculation.
We used the footpad inoculation route to evaluate whether
mck influenced dissemination to salivary glands as it does
following i.p. inoculation (8, 19, 49). This inoculation
route introduces virus in the periphery at a location more distal to
organs and tissues that become involved during acute infection. This
route may also be considered a model of natural transmission that is dependent on animal behavior such as biting. The impact of
mck on viral dissemination was examined in several
independent experiments (Fig. 5). We
observed lower virus titers in the salivary glands at day 7 or 14 postinoculation with RM461 than with K181+ or
rescued virus RQ461 (Fig. 5K and L). Following either i.p. or footpad
inoculation, mck mutant or wild-type viruses reached peak
levels in the salivary glands between days 14 and 21 and began to
decrease by day 28 (8, 55; J. Huang, unpublished data).
Footpads (Fig. 5A and B), draining popliteal lymph nodes (Fig. 5C and
D), and organs such as the liver and spleen (Fig. 5E through H) showed
similar titers for all viruses tested. Except for the significantly
reduced titers in the salivary glands, growth of the mck
mutant viruses could not be distinguished from that of the wild-type
virus. Although a report (19) suggested that viral
replication in the spleen and liver may be influenced by mck, we have not detected any consistent differences (Fig. 5
and data not shown). In our experiments, variable virus titers in the
spleen, liver, and lungs have sometimes been observed (8), but these differences are not consistently associated with a particular virus genotype, as exemplified by the data in Fig. 5I and J.
|
|
|
Modulation of foot swelling by mck.
Foot
thickness, measured with a caliper, can provide an indicator of local
inflammatory responses, particularly in conjunction with direct
histological evaluation of tissue sections (62, 64, 65).
Groups of 3-week-old BALB/c mice were inoculated (106 PFU) with mck mutant or rescued
virus, and the foot thickness of restrained mice was measured before
and at 0.5, 1, 2, 3, 4, 5, 7, 10, and 14 days after inoculation
using a digital caliper (Mitutoyo, Kanagawa, Japan). Virus-infected
mice did not show outward signs of illness, so to control investigator
bias, all inocula were coded. Foot swelling was defined as the percent
increase in thickness relative to the preinoculation measurement. This variation in foot thickness in different groups of mice was found to be
low, between 0.3 and 0.7%, based on measurements taken over a 2-week
period. We found that mck mutant virus RM461 induced significantly less swelling than either rescued virus RQ461 (Fig. 7A) or parental wild-type virus
K181+ (data not shown). A consistent pattern
developed by day 2, when the level of swelling in RQ461-inoculated feet
increased markedly, about 50% over preinoculation levels, compared to
the results obtained with RM461. These levels were maintained through
day 5, started to decline by day 7, and approached baseline by day 14 for all viruses. All swelling resulted from the effects of virus in the
inoculum because tissue culture medium alone failed to elicit any
response (data not shown). The differences in swelling corresponded to
the expected timing of expression of MCK-2 (35), starting
at day 2, and were consistently observed in several independent experiments (Fig. 7). Swelling continued throughout the period during
which viral replication was detected (Fig. 5A and B). The induction of
an mck-dependent swelling response correlated with the true
late (
2) kinetics of mck expression
(35). Swelling before 48 h, when MCK-2 is expressed,
was variable without regard to virus genotype or inoculum dose. The
appearance of dramatic, sustained differences in inflammation starting
at day 2 provided confirmation for the suggested proinflammatory role
of mck (19, 49).
|
Modulation of local inflammation by mck.
In
order to directly investigate cellular infiltrates in response to
mck, BALB/c mouse footpads were inoculated with mutant virus
RM461 or rescued virus RQ461 (106 PFU). Feet were
collected from sacrificed mice at 48 h postinoculation, and
midline longitudinal sections were prepared from 10% neutral buffered
formalin-fixed (Ex Cal II; Fisher Scientific), paraffin-embedded (Histo
Tech, Inc.) blocks. Examination by light microscopy at a low power
(×40) revealed substantially larger amounts of both cellularity and
edema in mck-expressing virus- than in control virus-infected feet (Fig. 8). All areas
of inoculated feet (dorsal, internal, and ventral) appeared less
inflamed following infection with mutant virus RM461 (Fig. 8B) than
following infection with mck-expressing control virus RQ461
(Fig. 8A). The differences in foot thickness measured grossly using
calipers (Fig. 7) correlated with the histopathological findings and
appeared to result from increases in both cellularity and edema (Fig.
8A and B). In a pattern that was readily appreciated at a low power,
the expression of mck correlated with a much more intense
local inflammatory response in the regions closest to the inoculation
sites. At a higher power (×400), differences in cellular infiltrates
with increased neutrophils were readily apparent, and there was more necrosis in tissues from mck-expressing virus-infected mice
(Fig. 8C) than in those from mutant virus-infected mice (Fig. 8D). All of these inflammatory changes were due to the presence of virus in the
inoculum, because injection of culture medium alone failed to induce
any response over that seen in sham (medium)-inoculated controls (data
not shown). These observations suggested that the expression of
mck altered and intensified the innate inflammatory response
to virus infection.
|
|
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by PHS grants AI30363 and AI33852 (to E.S.M.) as well as PHS training grant T32 GM07328 (to N.S.) and PHS Clinical Scientist Career Development Award K08 AI 01638 (to S.A.A.).
We thank Jing Huang for excellent technical assistance.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Microbiology and Immunology, Stanford University School of Medicine, Sherman Fairchild Science Building, Stanford, CA 94305-5124. Phone: (650) 723-6435. Fax: (650) 723-1606. E-mail: mocarski{at}stanford.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Ahn, K.,
A. Angulo,
P. Ghazal,
P. A. Peterson,
Y. Yang, and K. Fruh.
1996.
Human cytomegalovirus inhibits antigen presentation by a sequential multistep process.
Proc. Natl. Acad. Sci. USA
93:10990-10995 |
| 2. | Alam, R., D. Kumar, D. Anderson-Walters, and P. A. Forsythe. 1994. Macrophage inflammatory protein-1 alpha and monocyte chemoattractant peptide-1 elicit immediate and late cutaneous reactions and activate murine mast cells in vivo. J. Immunol. 152:1298-1303[Abstract]. |
| 3. | Baggiolini, M., B. Dewald, and B. Moser. 1997. Human chemokines: an update. Annu. Rev. Immunol. 15:675-705[CrossRef][Medline]. |
| 4. | Baggiolini, M., and P. Loetscher. 2000. Chemokines in inflammation and immunity. Immunol. Today 21:418-420[CrossRef][Medline]. |
| 5. |
Bale, J. F., Jr., and M. E. O'Neil.
1989.
Detection of murine cytomegalovirus DNA in circulating leukocytes harvested during acute infection of mice.
J. Virol.
63:2667-2673 |
| 6. |
Boshoff, C.,
Y. Endo,
P. D. Collins,
Y. Takeuchi,
J. D. Reeves,
V. L. Schweickart,
M. A. Siani,
T. Sasaki,
T. J. Williams,
P. W. Gray,
P. S. Moore,
Y. Chang, and R. A. Weiss.
1997.
Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines.
Science
278:290-294 |
| 7. | Butcher, E. C., M. Williams, K. Youngman, L. Rott, and M. Briskin. 1999. Lymphocyte trafficking and regional immunity. Adv. Immunol. 72:209-253[Medline]. |
| 8. | Cardin, R. D., J. M. Boname, G. B. Abenes, S. A. Jennings, and E. S. Mocarski. 1993. Reactivation of murine cytomegalovirus from latency, p. 65-74. In S. Michelson, and S. A. Plotkin (ed.), Multidisciplinary approaches to understanding cytomegalovirus disease. Elsevier, Amsterdam, The Netherlands. |
| 9. |
Clark-Lewis, I.,
B. Dewald,
M. Loetscher,
B. Moser, and M. Baggiolini.
1994.
Structural requirements for interleukin-8 function identified by design of analogs and CXC chemokine hybrids.
J. Biol. Chem.
269:16075-16081 |
| 10. | Clark-Lewis, I., K. S. Kim, K. Rajarathnam, J. H. Gong, B. Dewald, B. Moser, M. Baggiolini, and B. D. Sykes. 1995. Structure-activity relationships of chemokines. J. Leukoc. Biol. 57:703-711[Abstract]. |
| 11. | Collins, P. D., P. J. Jose, and T. J. Williams. 1991. The sequential generation of neutrophil chemoattractant proteins in acute inflammation in the rabbit in vivo. Relationship between C5a and proteins with the characteristics of IL-8/neutrophil-activating protein 1. J. Immunol. 146:677-684[Abstract]. |
| 12. |
Collins, T. M.,
M. R. Quirk, and M. C. Jordan.
1994.
Biphasic viremia and viral gene expression in leukocytes during acute cytomegalovirus infection of mice.
J. Virol.
68:6305-6311 |
| 13. |
Dairaghi, D. J.,
R. A. Fan,
B. E. McMaster,
M. R. Hanley, and T. J. Schall.
1999.
HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines.
J. Biol. Chem.
274:21569-21574 |
| 14. | Dairaghi, D. J., D. R. Greaves, and T. J. Schall. 1998. Abduction of chemokine elements by herpesviruses. Semin. Virol. 8:377-385[CrossRef]. |
| 15. |
Damon, I.,
P. M. Murphy, and B. Moss.
1998.
Broad spectrum chemokine antagonistic activity of a human poxvirus chemokine homolog.
Proc. Natl. Acad. Sci. USA
95:6403-6407 |
| 16. |
Endres, M. J.,
C. G. Garlisi,
H. Xiao,
L. Shan, and J. A. Hedrick.
1999.
The Kaposi's sarcoma-related herpesvirus (KSHV)-encoded chemokine vMIP-I is a specific agonist for the CC chemokine receptor (CCR)8.
J. Exp. Med.
189:1993-1998 |
| 17. | Farrell, H. E., H. Vally, D. M. Lynch, P. Fleming, G. R. Shellam, A. A. Scalzo, and N. J. Davis-Poynter. 1997. Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo. Nature 386:510-514[CrossRef][Medline]. |
| 18. | Feinberg, A. P., and B. Vogelstein. 1984. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem. 137:266-267[CrossRef][Medline]. |
| 19. |
Fleming, P.,
N. Davis-Poynter,
M. Degli-Esposti,
E. Densley,
J. Papadimitriou,
G. Shellam, and H. Farrell.
1999.
The murine cytomegalovirus chemokine homolog, m131/129, is a determinant of viral pathogenicity.
J. Virol.
73:6800-6809 |
| 20. |
Gao, J. L., and P. M. Murphy.
1994.
Human cytomegalovirus open reading frame US28 encodes a functional beta chemokine receptor.
J. Biol. Chem.
269:28539-28542 |
| 21. | Gerna, G., D. Zipeto, E. Percivalle, M. Parea, M. G. Revello, R. Maccario, G. Peri, and G. Milanesi. 1992. Human cytomegalovirus infection of the major leukocyte subpopulations and evidence for initial viral replication in polymorphonuclear leukocytes from viremic patients. J. Infect. Dis. 166:1236-1244[Medline]. |
| 22. | Hengel, H., W. Brune, and U. H. Koszinowski. 1998. Immune evasion by cytomegalovirus-survival strategies of a highly adapted opportunist. Trends Microbiol. 6:190-197[CrossRef][Medline]. |
| 23. | Hengel, H., U. Reusch, A. Gutermann, H. Ziegler, S. Jonjic, P. Lucin, and U. H. Koszinowski. 1999. Cytomegaloviral control of MHC class I function in the mouse. Immunol. Rev. 168:167-176[CrossRef][Medline]. |
| 24. | Ho, M. 1991. Cytomegalovirus: biology and infection, 2nd ed., p. 327-353. Plenum Publishing Corp., New York, N.Y. |
| 25. | Jones, T. R., and L. Sun. 1997. Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains. J. Virol. 71:2970-2979[Abstract]. |
| 26. |
Kledal, T. N.,
M. M. Rosenkilde,
F. Coulin,
G. Simmons,
A. H. Johnsen,
S. Alouani,
C. A. Power,
H. R. Luttichau,
J. Gerstoft,
P. R. Clapham,
I. Clark-Lewis,
T. N. C. Wells, and T. W. Schwartz.
1997.
A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus.
Science
277:1656-1659 |
| 27. | Koszinowski, U. H., M. del Val, and M. J. Reddehase. 1990. Cellular and molecular basis of the protective immune response to cytomegalovirus infection. Curr. Top. Microbiol. Immunol. 154:189-220[Medline]. |
| 28. |
Krathwohl, M. D.,
R. Hromas,
D. R. Brown,
H. E. Broxmeyer, and K. H. Fife.
1997.
Functional characterization of the CC chemokine-like molecules encoded by molluscum contagiosum virus types 1 and 2.
Proc. Natl. Acad. Sci. USA
94:9875-9880 |
| 29. | Lalani, A. S., J. W. Barrett, and G. McFadden. 2000. Modulating chemokines: more lessons from viruses. Immunol. Today 21:100-106[CrossRef][Medline]. |
| 30. |
Lee, L. F.,
P. Wu,
D. Sui,
D. Ren,
J. Kamil,
H. J. Kung, and R. L. Witter.
2000.
The complete unique long sequence and the overall genomic organization of the GA strain of Marek's disease virus.
Proc. Natl. Acad. Sci. USA
97:6091-6096 |
| 31. |
Leong, C. C.,
T. L. Chapman,
P. J. Bjorkman,
D. Formankova,
E. S. Mocarski,
J. H. Phillips, and L. L. Lanier.
1998.
Modulation of natural killer cell cytotoxicity in human cytomegalovirus infection: the role of endogenous class I major histocompatibility complex and a viral class I homolog.
J. Exp. Med.
187:1681-1687 |
| 32. | Lin, Y.-C. 1997. Ph.D. thesis. Stanford University, Stanford, Calif. |
| 33. | Liu, J. L., S. F. Lin, L. Xia, P. Brunovskis, D. Li, I. Davidson, L. F. Lee, and H. J. Kung. 1999. MEQ and V-IL8: cellular genes in disguise? Acta Virol. 43:94-101[Medline]. |
| 34. | Loetscher, P., M. Seitz, I. Clark-Lewis, M. Baggiolini, and B. Moser. 1996. Activation of NK cells by CC chemokines. Chemotaxis, Ca2+ mobilization, and enzyme release. J. Immunol. 156:322-327[Abstract]. |
| 35. |
MacDonald, M. R.,
M. W. Burney,
S. B. Resnick, and H. I. Virgin.
1999.
Spliced mRNA encoding the murine cytomegalovirus chemokine homolog predicts a beta chemokine of novel structure.
J. Virol.
73:3682-3691 |
| 36. | MacDonald, M. R., X. Y. Li, and H. W. Virgin, IV. 1997. Late expression of a beta chemokine homolog by murine cytomegalovirus. J. Virol. 71:1671-1678[Abstract]. |
| 37. |
Manning, W. C.,
C. A. Stoddart,
L. A. Lagenaur,
G. B. Abenes, and E. S. Mocarski.
1992.
Cytomegalovirus determinant of replication in salivary glands.
J. Virol.
66:3794-3802 |
| 38. | McFadden, G., A. Lalani, H. Everett, P. Nash, and X. Xu. 1998. Virus-encoded receptors for cytokines and chemokines. Semin. Cell Dev. Biol. 9:359-368[CrossRef][Medline]. |
| 39. | Mocarski, E. S., and C. T. Courcelle. 2001. Cytomegaloviruses and their replication, p. 2629-2673. In D. M. Knipe, and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott-Williams & Wilkins, Philadelphia, Pa. |
| 40. |
Moore, P. S.,
C. Boshoff,
R. A. Weiss, and Y. Chang.
1996.
Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV.
Science
274:1739-1744 |
| 41. | Neote, K., D. DiGregorio, J. Y. Mak, R. Horuk, and T. J. Schall. 1993. Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell 72:415-425[CrossRef][Medline]. |
| 42. | Pass, R. F. 2001. Cytomegalovirus, p. 2675-2705. In D. M. Knipe, and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott-Williams & Wilkins, Philadelphia, Pa. |
| 43. |
Penfold, M. E.,
D. J. Dairaghi,
G. M. Duke,
N. Saederup,
E. S. Mocarski,
G. W. Kemble, and T. J. Schall.
1999.
Cytomegalovirus encodes a potent alpha chemokine.
Proc. Natl. Acad. Sci. USA
96:9839-9844 |
| 44. | Prichard, M. N., G. M. Duke, and E. S. Mocarski. 1996. Human cytomegalovirus uracil DNA glycosylase is required for the normal temporal regulation of both DNA synthesis and viral replication. J. Virol. 70:3018-3025[Abstract]. |
| 45. | Rajarathnam, K., B. D. Sykes, B. Dewald, M. Baggiolini, and I. Clark-Lewis. 1999. Disulfide bridges in interleukin-8 probed using non-natural disulfide analogues: dissociation of roles in structure from function. Biochemistry 38:7653-7658[CrossRef][Medline]. |
| 46. | Rawlinson, W. D., H. E. Farrell, and B. G. Barrell. 1996. Analysis of the complete DNA sequence of murine cytomegalovirus. J. Virol. 70:8833-8849[Abstract]. |
| 47. | Reyburn, H. T., O. Mandelboim, M. Vales-Gomez, D. M. Davis, L. Pazmany, and J. L. Strominger. 1997. The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells. Nature 386:514-517[CrossRef][Medline]. |
| 48. | Rossi, D., and A. Zlotnik. 2000. The biology of chemokines and their receptors. Annu. Rev. Immunol. 18:217-242[CrossRef][Medline]. |
| 49. |
Saederup, N.,
Y. C. Lin,
D. J. Dairaghi,
T. J. Schall, and E. S. Mocarski.
1999.
Cytomegalovirus-encoded beta chemokine promotes monocyte-associated viremia in the host.
Proc. Natl. Acad. Sci. USA
96:10881-10886 |
| 50. | Sallusto, F., C. R. Mackay, and A. Lanzavecchia. 2000. The role of chemokine receptors in primary, effector, and memory immune responses. Annu. Rev. Immunol. 18:593-620[CrossRef][Medline]. |
| 51. | Saltzman, R. L., M. R. Quirk, and M. C. Jordan. 1988. Disseminated cytomegalovirus infection. Molecular analysis of virus and leukocyte interactions in viremia. J. Clin. Investig. 81:75-81. |
| 52. | Smith, G. L., J. A. Symons, A. Khanna, A. Vanderplasschen, and A. Alcami. 1997. Vaccinia virus immune evasion. Immunol. Rev. 159:137-154[CrossRef][Medline]. |
| 53. | Spriggs, M. K. 1996. One step ahead of the game: viral immunomodulatory molecules. Annu. Rev. Immunol. 14:101-130[CrossRef][Medline]. |
| 54. |
Stine, J. T.,
C. Wood,
M. Hill,
A. Epp,
C. J. Raport,
V. L. Schweickart,
Y. Endo,
T. Sasaki,
G. Simmons,
C. Boshoff,
P. Clapham,
Y. Chang,
P. Moore,
P. W. Gray, and D. Chantry.
2000.
KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells.
Blood
95:1151-1157 |
| 55. |
Stoddart, C. A.,
R. D. Cardin,
J. M. Boname,
W. C. Manning,
G. B. Abenes, and E. S. Mocarski.
1994.
Peripheral blood mononuclear phagocytes mediate dissemination of murine cytomegalovirus.
J. Virol.
68:6243-6253 |
| 56. | Streblow, D. N., C. Soderberg-Naucler, J. Vieira, P. Smith, E. Wakabayashi, F. Ruchti, K. Mattison, Y. Altschuler, and J. A. Nelson. 1999. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell 99:511-520[CrossRef][Medline]. |
| 57. |
Takebe, Y.,
M. Seiki,
J. Fujisawa,
P. Hoy,
K. Yokota,
K. Arai,
M. Yoshida, and N. Arai.
1988.
SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat.
Mol. Cell. Biol.
8:466-472 |
| 58. | Taub, D. D., J. R. Ortaldo, S. M. Turcovski-Corrales, M. L. Key, D. L. Longo, and W. J. Murphy. 1996. Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. J. Leukoc. Biol. 59:81-89[Abstract]. |
| 59. |
van Den Pol, A. N.,
E. Mocarski,
N. Saederup,
J. Vieira, and T. J. Meier.
1999.
Cytomegalovirus cell tropism, replication, and gene transfer in brain.
J. Neurosci.
19:10948-10965 |
| 60. |
Vieira, J.,
H. E. Farrell,
W. D. Rawlinson, and E. S. Mocarski.
1994.
Genes in the HindIII J fragment of the murine cytomegalovirus genome are dispensable for growth in cultured cells: insertion mutagenesis with a lacZ/gpt cassette.
J. Virol.
68:4837-4846 |
| 61. | Wiertz, E., A. Hill, D. Tortorella, and H. Ploegh. 1997. Cytomegaloviruses use multiple mechanisms to elude the host immune response. Immunol. Lett. 57:213-216[CrossRef][Medline]. |
| 62. | Wilson, S. D., V. K. Kuchroo, D. I. Israel, and M. E. Dorf. 1990. Expression and characterization of TCA3: a murine inflammatory protein. J. Immunol. 145:2745-2750[Abstract]. |
| 63. | Witt, D. P., and A. D. Lander. 1994. Differential binding of chemokines to glycosaminoglycan subpopulations. Curr. Biol. 4:394-400[CrossRef][Medline]. |
| 64. |
Wolpe, S. D.,
G. Davatelis,
B. Sherry,
B. Beutler,
D. G. Hesse,
H. T. Nguyen,
L. L. Moldawer,
C. F. Nathan,
S. F. Lowry, and A. Cerami.
1988.
Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties.
J. Exp. Med.
167:570-581 |
| 65. |
Wolpe, S. D.,
B. Sherry,
D. Juers,
G. Davatelis,
R. W. Yurt, and A. Cerami.
1989.
Identification and characterization of macrophage inflammatory protein 2.
Proc. Natl. Acad. Sci. USA
86:612-616 |
| 66. | Wuyts, A., N. Van Osselaer, A. Haelens, I. Samson, P. Herdewijn, A. Ben-Baruch, J. J. Oppenheim, P. Proost, and J. Van Damme. 1997. Characterization of synthetic human granulocyte chemotactic protein 2: usage of chemokine receptors CXCR1 and CXCR2 and in vivo inflammatory properties. Biochemistry 36:2716-2723[CrossRef][Medline]. |
| 67. |
Zou, P.,
Y. Isegawa,
K. Nakano,
M. Haque,
Y. Horiguchi, and K. Yamanishi.
1999.
Human herpesvirus 6 open reading frame U83 encodes a functional chemokine.
J. Virol.
73:5926-5933 |
This article has been cited by other articles:
| ||||||||||||||||||||||||||